Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients

Withdrawn before enrolling · Phase 2

Conditions studied: Migraine in Children, Pain, Neuropathic

In brief

Single-center, open-label, pre-post treatment pilot study to evaluate the safety and effectiveness of sphenopalatine ganglia blocks for the treatment of chronic migraine in the pediatric population. 50 children with a diagnosis of chronic migraines will undergo a series of three transnasal sphenopalatine ganglia blocks to measure their effect on headache frequency, headache intensity, headache duration, and use of headache medication.

Key facts

Study ID

NCT04466826

Run by

Washington University School of Medicine

People needed

0

Starts

2021-01-02

Expected to finish

2021-02-05

Last updated by the study team

2021-02-10

Who can join

Age: 8 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children ages 8 to 17 years old Meet the criteria for chronic migraines Have remained stable on their current headache medication for a minimum of 4 weeks.
• Able to provide informed consent from parent or legal guardian Able to provide assent if subject is a minor of appropriate age

You may not qualify if…

• Allergy to local anesthetic Developmental delay (e.g. non-verbal) Inability to use numeric pain scale Inability to perform or tolerate transnasal procedure Substance abuse disorders Known pregnancy

Where it is running

• St. Louis Children's Hospital — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.